OLIPASS Corporation, a biotech company, focuses on developing therapeutic products in South Korea. The company develops its products using its novel PNA based technologies. Its products pipeline includes SCN9A, a product candidate that is in Phase II clinical trials for the treatment of pain. The company also develops PCSK9 for the treatment of hyper cholesterolemia; VEGF for the treatment of AMD/DR; HIF-1a for chemo/radio-sensitizer treatment; Dystrophin for the treatment of duchenne muscular disease; and PTP1B for the treatment of type II diabetes. It is also involved in the development of CTLA4 immuno-oncology, PD1 immuno-oncology, and NOX4 fibrosis. In addition, the company engages in the collaborative research and development with OliPass Cosmeceuticals for life style management solutions, as well as Target X1 and Target X2. OLIPASS Corporation was founded in 2006 and is headquartered in Yongin-si, South Korea.
तुलना करने के लिए मीट्रिक्स | 244460 | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंध244460पीअर्सक्षेत्र | |
---|---|---|---|---|
पी/ई अनुपात | 0.0x | −3.4x | −0.6x | |
PEG अनुपात | 0.00 | 0.07 | 0.00 | |
क़ीमत/बुक | 0.0x | 2.2x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 0.0x | 21.9x | 3.1x | |
अपसाइड (विश्लेषक लक्ष्य) | 0.0% | 35.0% | 53.6% | |
उचित मूल्य अपसाइड | अनलॉक करें | 19.5% | 8.0% | अनलॉक करें |